{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:48:48Z","timestamp":1785293328976,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ijtb.2019.10.002","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:46:38Z","timestamp":1571255198000},"page":"29-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis"],"prefix":"10.1016","volume":"67","author":[{"given":"V.S.","family":"Salhotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.S.","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelima","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjani","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Padmapriyadarsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Mehandru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Jaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ponnuraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhur","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kalaiselvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almas","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Khaparde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2019.10.002_bib1","series-title":"Global Tuberculosis Report 2018","year":"2018"},{"key":"10.1016\/j.ijtb.2019.10.002_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/230240bc-bcf3-46b2-9b21-2e6e584f7333","article-title":"Multidrug-resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijtb.2019.10.002_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00134712","article-title":"Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes","volume":"42","author":"Falzon","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2019.10.002_bib4","series-title":"India TB Report 2018","year":"2018"},{"key":"10.1016\/j.ijtb.2019.10.002_bib5","series-title":"The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.ijtb.2019.10.002_bib6","series-title":"Division of AIDS Table for Grading the Severity of Adult and Paediatric Adverse Events Version 1.0","year":"2014"},{"issue":"5","key":"10.1016\/j.ijtb.2019.10.002_bib7","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2019.10.002_bib8","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.06126-11","article-title":"Randomized pilot trial of eight weeks of bedaquiline treatment for multidrug-resistant tuberculosis: long term outcome, tolerability, and effect on the emergence of drug resistance","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2019.10.002_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ijtb.2019.10.002_bib10","doi-asserted-by":"crossref","first-page":"1801528","DOI":"10.1183\/13993003.01528-2018","article-title":"High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen","volume":"52","author":"Ndjeka","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ijtb.2019.10.002_bib11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"Compassionate use of Bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis a French Cohort","volume":"60","author":"Guglielmetti","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ijtb.2019.10.002_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.5588\/ijtld.14.0944","article-title":"Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis","volume":"19","author":"Ndjeka","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.ijtb.2019.10.002_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0451","article-title":"Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"16","author":"Cox","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"10.1016\/j.ijtb.2019.10.002_bib14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ijtb.2019.10.002_bib15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jac\/dks389","article-title":"Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"68","author":"Dey","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"10150","key":"10.1016\/j.ijtb.2019.10.002_bib16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijtb.2019.10.002_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1017\/S0950268810000907","article-title":"Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients","volume":"139","author":"Podewils","year":"2011","journal-title":"Epidemiol Infect"},{"issue":"2","key":"10.1016\/j.ijtb.2019.10.002_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5588\/pha.17.0013","article-title":"Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients","volume":"7","author":"Suryawanshi","year":"2017","journal-title":"Public Health Action"},{"key":"10.1016\/j.ijtb.2019.10.002_bib19","series-title":"Guidance Document: Nutritional Care and Support for Patients with Tuberculosis in India","year":"2019"},{"key":"10.1016\/j.ijtb.2019.10.002_bib20","series-title":"Direct Benefit Transfer. Government of India. Nikshay-TB patient incentive for nutritional support","year":"2019"},{"key":"10.1016\/j.ijtb.2019.10.002_bib21","series-title":"Rapid Communication: Key Changes to the Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR\/RR-TB)","year":"2018"},{"key":"10.1016\/j.ijtb.2019.10.002_bib22","author":"Clinical Trials Registry of India"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570719303865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570719303865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:24:28Z","timestamp":1762176268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570719303865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0019570719303865"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2019.10.002","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2019.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of Tuberculosis Association of India.","name":"copyright","label":"Copyright"}]}}